IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Agger et al.
Appl. No.	:	10/563,731
Filed	:	January 6, 2006
For	:	ADJUVANT COMBINATIONS OF LIPOSOMES AND MYCOBACTERIAL LIPIDS FOR IMMUNIZATION COMPOSITIONS AND VACCINES
Examiner	:	Unknown
Group Art Unit	:	Unknown

REQUEST FOR CORRECTED PATENT PUBLICATION UNDER 37 C.F.R. 1.221(b)

Mail Stop PCT
Commissioner for Patents
Mail Stop AF
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants hereby request correction of the title of Published US Patent Application No. 2006/0286128. There is a misspelled word ("MYCOBACTERIAIAL") in the title of the published application as shown on the enclosed, marked-up first page of the published application. This word should be –MYCOBACTERIAL--. Also enclosed herewith is the first page of the application as filed (PCT WO2005/004911) that shows the correct title. Thus, the proper title of the published application should be:

ADJUVANT COMBINATIONS OF LIPOSOMES AND MYCOBACTERIAL LIPIDS FOR IMMUNIZATION COMPOSITIONS AND VACCINES

Because this is an error on the part of the USPTO, and the request is being made within two months of the publication date of December 21, 2006, no fees are believed due. However, if any fees are due, please charge Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: February 21, 2007

By: 

Neil S. Bartfeld, Ph.D.
Registration No. 39,901
Agent of Record
Customer No. 20,995
(619) 235-8550

3452348
022107

US 20060286128A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2006/0286128 A1**

Agger (43) **Pub. Date: Dec. 21, 2006**

(54) **ADJUVANT COMBINATIONS OF LIPOSOMES AND ~~MYCOBACTERIAL~~ LIPIDS FOR IMMUNIZATION COMPOSITIONS AND VACCINES** MYCOBACTERIAL

(76) Inventor: **Else Agger**, Copenhagen (DK)

Correspondence Address:
KNOBBE MARTENS OLSON & BEAR LLP
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614 (US)

(21) Appl. No.: **10/563,731**

(22) PCT Filed: **Jul. 7, 2004**

(86) PCT No.: **PCT/DK04/00488**

(30) **Foreign Application Priority Data**

Jul. 9, 2003 (DK) PA200301046
Sep. 27, 2003 (DK) PA200301403

Publication Classification

(51) **Int. Cl.**
A61K 39/04 (2006.01)
(52) **U.S. Cl.** **424/248.1**

(57) **ABSTRACT**

The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldioctadecylammonium-bromide/chloride (DDA) and a lipid extract from The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldioctadecylammonium-bromide/chloride (DDA) and a lipid extract from *Mycobacterium bovis*. The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldioctadecylammonium-bromide/chloride (DDA) and a lipid extract from *Mycobacterium bovis*<The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldioctadecylammonium-bromide/chloride (DDA) and a lipid extract from *Mycobacterium bovis* BCG The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldioctadecylammonium-bromide/chloride (DDA) and a lipid extract from *Mycobacterium bovis* BCG <The present invention provides a vaccin adjuvant consisting of a combination of a surfactant i.e. dimethyldioctadecylammonium-bromide/chloride (DDA) and a lipid extract from *Mycobacterium bovis* BCG. The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldioctadecylammonium-bromide/chloride (DDA) and a lipid extract from <i>*Mycobacterium bovis* BCG<i>. <The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldioctadecylammonium-bromide/chloride (DDA) and a lipid extract from <i>*Mycobacterium bovis* BCG<i>. The total lipid extract contains both apolar lipids, polar lipids, and lipids of intermediate polarity of which the apolar lipids were found to induce the most powerful immune responses. The total lipids may be extracted with chloroform/methanol and re-dissolved in water before the addition of surfactant. This preparation may be used to induce prominent cell-mediated immune responses in a mammal in order to combat pathogens, or as a treatment for cancer.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 January 2005 (20.01.2005)

PCT

(10) International Publication Number
WO 2005/004911 A2

(51) International Patent Classification[7]: A61K 39/39, 39/04, A61P 31/06

(21) International Application Number: PCT/DK2004/000488

(22) International Filing Date: 7 July 2004 (07.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2003 01046 9 July 2003 (09.07.2003) DK
PA 2003 01403 27 September 2003 (27.09.2003) DK

(71) Applicant (*for all designated States except US*): STATENS SERUM INSTITUT [DK/DK]; Artillerivej 5, DK-2300 Copenhagen S (DK).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): AGGER, Else, Marie [DK/DK]; Krudtmøllegårds Allé 9, DK-2300 Copenhagen S (DK). ANDERSEN, Peter [DK/DK]; Sparreholmvej 47, DK-2700 Brønshøj (DK). OLSEN, Anja [DK/DK]; Jacob Bulls Allé 121, DK-2860 Søborg (DK). ROSENKRANDS, Ida [DK/DK]; Kastanievaven 9, DK-3500 Værløse (DK).

(74) Common Representative: TOFT, Lars; Statens Serum Institut, Corporate Affairs, Artillerivej 5, DK-2300 Copenhagen S (DK).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

[Continued on next page]

(54) Title: ADJUVANT COMBINATIONS OF LIPOSOMES AND MYCOBACTERIAL LIPIDS FOR IMMUNIZATION COMPOSITIONS AND VACCINES



(57) Abstract: The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldioctadecylammonium-bromide/chloride (DDA) and a lipid extract from *Mycobacterium bovis* BCG. The total lipid extract contains both apolar lipids, polar lipids, and lipids of intermediate polarity of which the apolar lipids were found to induce the most powerful immune responses. The total lipids may be extracted with chloroform/methanol and re-dissolved in water before the addition of surfactant. This preparation may be used to induce prominent cell-mediated immune responses in a mammal in order to combat pathogens, or as a treatment for cancer.

WO 2005/004911 A2